16 Results for "

cocktail

" in MedChemExpress (MCE) Product Catalog:
Products (16)

16 Results for "cocktail" in MCE Product Catalog:

2066
2066 Publications Verification
Cat. No.: HY-K0010

MCE Protease Inhibitor Cocktail (EDTA-Free, 100× in DMSO) is a blend of 6 pan-protease inhibitors for protection of protein integrity.The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

loading...
    loading...
722
722 Cited Publications
Cat. No.: HY-K0021

Phosphatase Inhibitor Cocktail I (100× in DMSO) is a blend of 2 phosphatase inhibitors that can effectively inhibit alkaline phosphatases and serine/threonine phosphatases. It is used to maintain the phosphorylation status of proteins.The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

loading...
    loading...
479
479 Cited Publications
Cat. No.: HY-K0022

Phosphatase Inhibitor Cocktail Ⅱ (100× in ddH2O) is a blend of 5 phosphatase inhibitors that can broadly inhibit acid phosphatases, alkaline phosphatases, and protein tyrosine phosphatases (PTPs).The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

loading...
    loading...
258
258 Cited Publications
Cat. No.: HY-K0011

MCE Protease Inhibitor Cocktail, mini-Tablet (EDTA-Free) is a blend of 5 pan-protease inhibitors for protection of protein integrity. The 25 pcs is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

loading...
    loading...
244
244 Cited Publications
Cat. No.: HY-K0023

Phosphatase Inhibitor Cocktail Ⅲ (100× in DMSO) is a mixture of multiple phosphatase inhibitors that effectively inhibit serine/threonine phosphatases and alkaline phosphatases, and is used to preserve the phosphorylation status of proteins.The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

loading...
    loading...
151
151 Cited Publications
Cat. No.: HY-K0013

MCE Protease and Phosphatase Inhibitor Cocktail (EDTA-Free, 10× in ddH2O) protects protein from degradation by endogenous proteases released during protein extraction and purification.The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

loading...
    loading...
43
43 Cited Publications
Cat. No.: HY-K0030

MCE Deacetylase Inhibitor Cocktail is a synergistic combination of chemicals designed to preserve the acetylation state of proteins.The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-K0012

MCE Protease Inhibitor Cocktail, Bacteria (EDTA-Free, 100× in DMSO) protects proteins from degradation by endogenous proteases released during protein extraction and purification.The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-K1043

MCE CEPT Cocktail is composed of CET small molecules (Chroman 1, Emricasan and Trans-ISRIB) and Polyamine Solution, and can effectively enhance cell survival and promote clonal growth of genetically stable hPSCs.


loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-K0017

MCE Kinase Inhibitor Cocktail controls the biological activity of kinases. This inhibitor is primarily used for Biochemicals applications.The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

loading...
    loading...
Cat. No.: HY-W013268
CAS No.: 790676-40-3
Synonyms: (+)-N-3-Benzylnirvanol
Target:  

Cytochrome P450

Research Areas:  

Metabolic Disease

(S)-(+)-N-3-Benzylnirvanol ((+)-N-3-Benzylnirvanol) is a selective and competitive cytochrome P450 (CYP) isoform CYP2C19 inhibitor with a Ki of 250 nM. (S)-(+)-N-3-Benzylnirvanol has low activity against CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 .
loading...
    loading...
Cat. No.: HY-P99811
CAS No.: 944548-37-2
Synonyms: CR57

Target:  

RABV

Research Areas:  

Infection

Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .
loading...
    loading...
Cat. No.: HY-K6021

MCE CEPT Cocktail Plus (1000×) is a composite supplement specifically formulated for pluripotent stem cell culture. Through synergistic effects, it inhibits oxidative damage, blocks apoptotic pathways, and regulates protein translation, significantly reducing cellular stress levels through multiple targets. This dramatically improves the survival rate and cloning efficiency of pluripotent stem cells.

loading...
    loading...
Cat. No.: HY-P992155
Synonyms: Arevirumab-3

Target:  

Arenavirus

Research Areas:  

Infection

Arevirumab (Arevirumab-3) is a pan-lineage neutralizing human monoclonal antibody cocktail (8.9F, 12.1F, 37.D). Arevirumab protects cynomolgus monkeys from severe Lassa fever caused by lineage II and III LASV isolates. Arevirumab is applicable to research related to Lassa fever .
loading...
    loading...
Cat. No.: HY-K1043A

MCE Polyamine Supplement (1000×) can be used as a component of the CEPT Cocktail in combination with Emricasan, Chroman 1, and trans-ISRIB to enhance the survival of pluripotent stem cells (PSCs) and promote single-cell clonal expansion. In addition, this supplement improves the viability of PSCs and their differentiated derivatives during cryopreservation, organoid culture, single-cell cloning, and genome editing, thereby enhancing the robustness and reproducibility of downstream applications.

loading...
    loading...
Cat. No.: HY-L073
395 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 395 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

  • 1